SCHEMBL24258313

SCHEMBL24258313

CNCc1ccc(-n2ccc(C)n2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.49
PARP1 P09874 8/20 0.42
PARP2 Q9UGN5 1/20 0.42
PARP3 Q9Y6F1 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
HDAC4 P56524 1/20 0.41
MAPT P10636 3/20 0.41
ATM Q13315 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NCF1 P14598 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
LOXL2 Q9Y4K0 1/20 0.39
CYP3A4 P08684 1/20 0.38
TDO2 P48775 1/20 0.38
AVPR2 P30518 1/20 0.37
OXTR P30559 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201994 0.80 HTT (0.53) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL8222456 0.79 HTT (0.51) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL17924409 0.79 HTT (0.51) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL17090986 0.79 HTT (0.51) HTTRAB9ANPC1HDAC4MAPT
Hydrochloric Acid SCHEMBL17091212 0.77 HTT (0.50) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL21508059 0.76 NOS1 (0.42) PARP1PARP2RAB9ANPC1MAPT
SCHEMBL8221095 0.75 HTT (0.43) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL12422701 0.75 HTT (0.59) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL18725064 0.74 HTT (0.58) HTTRAB9ANPC1HDAC4MAPT
SCHEMBL20868291 0.72 NOTUM (0.58) PARP1PARP2PARP3NCF1LOXL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3177612-B1 OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES NUEVOLUTION AS (DK) 2022-02-23 EP disclosed